99 related articles for article (PubMed ID: 27345498)
1. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.
Thummarati P; Wijitburaphat S; Prasopthum A; Menakongka A; Sripa B; Tohtong R; Suthiphongchai T
World J Gastroenterol; 2012 Jan; 18(3):244-50. PubMed ID: 22294827
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.
Yatsenko T; Rios R; Nogueira T; Takahashi S; Tabe Y; Naito T; Takahashi K; Hattori K; Heissig B
Front Immunol; 2023; 14():1299792. PubMed ID: 38313435
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Mahmood N; Mihalcioiu C; Rabbani SA
Front Oncol; 2018; 8():24. PubMed ID: 29484286
[TBL] [Abstract][Full Text] [Related]
5. uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.
Uhl B; A Mittmann L; Dominik J; Hennel R; Smiljanov B; Haring F; B Schaubächer J; Braun C; Padovan L; Pick R; Canis M; Schulz C; Mack M; Gutjahr E; Sinn P; Heil J; Steiger K; Kanse SM; Weichert W; Sperandio M; Lauber K; Krombach F; Reichel CA
EMBO Mol Med; 2021 Jun; 13(6):e13110. PubMed ID: 33998175
[TBL] [Abstract][Full Text] [Related]
6. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.
Cochran BJ; Gunawardhana LP; Vine KL; Lee JA; Lobov S; Ranson M
BMC Biotechnol; 2009 May; 9():43. PubMed ID: 19442270
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.
Beaulieu LM; Whitley BR; Wiesner TF; Rehault SM; Palmieri D; Elkahloun AG; Church FC
Bioessays; 2007 Oct; 29(10):1029-38. PubMed ID: 17876797
[TBL] [Abstract][Full Text] [Related]
8. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Kenny HA; Leonhardt P; Ladanyi A; Yamada SD; Montag A; Im HK; Jagadeeswaran S; Shaw DE; Mazar AP; Lengyel E
Clin Cancer Res; 2011 Feb; 17(3):459-71. PubMed ID: 21149615
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model.
Furuya H; Hayashi K; Shimizu Y; Kim N; Tsukikawa Y; Chen R; Sun Y; Chan OTM; Pagano I; Peres R; Hokutan K; Igari F; Chan KS; Rosser CJ
J Transl Med; 2020 Feb; 18(1):57. PubMed ID: 32024545
[TBL] [Abstract][Full Text] [Related]
10. Decreased fertility in female mice lacking urokinase plasminogen activator.
Laurenzi G; Fedeli V; Canipari R
Reprod Biol; 2024 Mar; 24(1):100840. PubMed ID: 38113659
[TBL] [Abstract][Full Text] [Related]
11. A versatile engineered extracellular vesicle platform simultaneously targeting and eliminating senescent stromal cells and tumor cells to promote tumor regression.
Gong L; Chen Z; Feng K; Luo L; Zhang J; Yuan J; Ren Y; Wang Y; Zheng X; Li Q
J Nanobiotechnology; 2024 Mar; 22(1):105. PubMed ID: 38468249
[TBL] [Abstract][Full Text] [Related]
12. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
Montuori N; Pesapane A; Rossi FW; Giudice V; De Paulis A; Selleri C; Ragno P
Transl Med UniSa; 2016 Nov; 15():15-21. PubMed ID: 27896223
[TBL] [Abstract][Full Text] [Related]
13. The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.
O'Connell C; VandenHeuvel S; Kamat A; Raghavan S; Godin B
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077371
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells.
Dash S; Yoder S; Mesa T; Smith A; Cen L; Eschrich S; Armaiz-Pena GN; Monteiro ANA
Sci Rep; 2021 Jul; 11(1):14334. PubMed ID: 34253763
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract][Full Text] [Related]
16. Productive Cross-Talk with the Microenvironment: A Critical Step in Ovarian Cancer Metastasis.
Aziz MAAE; Agarwal K; Dasari S; Mitra AAK
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31640297
[TBL] [Abstract][Full Text] [Related]
17. Leptin-induced signaling pathways in cancer cell migration and invasion.
Ghasemi A; Saeidi J; Azimi-Nejad M; Hashemy SI
Cell Oncol (Dordr); 2019 Jun; 42(3):243-260. PubMed ID: 30877623
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Nakatsuka E; Sawada K; Nakamura K; Yoshimura A; Kinose Y; Kodama M; Hashimoto K; Mabuchi S; Makino H; Morii E; Yamaguchi Y; Yanase T; Itai A; Morishige KI; Kimura T
Oncotarget; 2017 Oct; 8(52):89887-89902. PubMed ID: 29163796
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
